NYSE:DPLO - Diplomat Pharmacy Stock Price, Forecast & News

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) announced its earnings results on Tuesday, November, 12th. The company reported ($2.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $2.15. The business had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a negative net margin of 12.47% and a negative return on equity of 12.15%. The firm's revenue for the quarter was down 5.3% compared to the same quarter last year. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of $-4.91--4.81 for the period, compared to the Thomson Reuters consensus EPS estimate of $-2.67. The company issued revenue guidance of $$4.9-5.1 billion, compared to the consensus revenue estimate of $$4.87 billion.

12 brokers have issued twelve-month target prices for Diplomat Pharmacy's stock. Their forecasts range from $3.00 to $30.00. On average, they expect Diplomat Pharmacy's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings and 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

News headlines about DPLO stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Diplomat Pharmacy.

Diplomat Pharmacy saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 4,290,000 shares, a decrease of 47.0% from the December 15th total of 8,090,000 shares. Based on an average daily volume of 2,220,000 shares, the days-to-cover ratio is presently 1.9 days. Currently, 7.4% of the company's stock are short sold. View Diplomat Pharmacy's Current Options Chain.

Some companies that are related to Diplomat Pharmacy include Rite Aid (RAD), Petmed Express (PETS), 111 (YI), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Ford Motor (F), Cara Therapeutics (CARA), CVS Health (CVS), General Motors (GM), Activision Blizzard (ATVI), Exelixis (EXEL) and Horizon Therapeutics (HZNP).

Diplomat Pharmacy's stock is owned by many different of retail and institutional investors. Top institutional investors include Syquant Capital Sas (0.12%), FNY Investment Advisers LLC (0.05%) and Advisors Preferred LLC (0.03%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was purchased by a variety of institutional investors in the last quarter, including Syquant Capital Sas, FNY Investment Advisers LLC and Advisors Preferred LLC. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $3.99.

Diplomat Pharmacy has a market capitalization of $303.24 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]